Gene therapy (GT) for hemophilia B using recombinant adeno-associated viral vectors (rAAVs) produced sufficient levels of factor IX (FIX) to prevent the need for prophylaxis; several AAV drugs have recently received regulatory approval for hemophilia B [8]. Here, F9 is linked to hemophilia B.